Changes coming in 2010 for first-line treatment of multiple myeloma

According to a study published by Majestic Research's Market Research Group, data presented at the 2009 American Society of Hematology (ASH) 2009 Annual Meeting in December has had a profound effect on the way many hematologists and oncologists intend to treat multiple myeloma, a cancer of the plasma cells.

Specifically, almost half of those specialists polled say they expect to start using the thalidomide analog Revlimid (lenalidomide), the antineoplastic agent Velcade (bortezomib), or both in combination.

Call

In this context, the most recalled study from ASH was MM-015, a Phase III study that looked at the continuous use of Revlimid with Melphalan and Prednisone. Research shows that many experts believed that the results of MM-015 were significant enough to encourage using Revlimid in treating multiple myeloma.

In short, this year we should expect a substantial change to the first-line treatment of this difficult-to-treat cancer.

By Ross Bonander
Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...